GLP-1R agonists can redefine chronic disease treatment beyond diabetes and obesity
GlobalData’s latest report showcases an analysis of the GLP-1R agonists pipeline in multiple indications, highlighting the areas…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Ozempic
Novo Nordisk’s Ozempic gains USFDA approves to cut risk of diabetic kidney disease progression
The approval was based on data from a late-stage study, which showed that Ozempic helped cut the risk of death from chronic kidney…
PCRM survey shows that most Americans don’t prefer new weight-loss drugs
The survey included 2,205 adults and was conducted on September 5, 2024
Cardiovascular benefits can increase Rybelsus’ competitiveness over other oral GLP-1RAs
The market for oral GLP-1RAs is expanding, and Rybelsus’ latest results showed its benefits in reducing the risk in cardiovascular…
US FDA flags dosing risks from compounded versions of Novo’s weight-loss drug
Regulator highlights risks of dosing errors and adverse events, urges healthcare providers to ensure correct syringe use and…
Ozempic linked with lower dementia risk, nicotine use, British study finds
The study, published in the Lancet's eClinicalMedicine journal, explored more than 100 million medical records of the U.S.…
WHO issues warnings on fake copies of Novo Nordisk’s weight-loss drugs
The warnings were issued on fake drugs claiming to contain the active ingredient found in Novo Nordisk's diabetes drug Ozempic…
GLP1 agonists set to become the best-selling drugs in 2024: GlobalData
Shift could reflect a changing demand away from oncology toward addressing metabolic disorders
Catalent to help Novo Nordisk address production demands for Ozempic and Wegovy: GlobalData
The acquisition of Catalent by Novo Holdings expects to see three new manufacturing sites added to Novo Nordisk’s arsenal, to…
US FDA approves Novo Nordisk’s Ozempic 2 mg to treat type-II diabetes
Ozempic demonstrated 2.1 per cent blood sugar reduction and also weight loss in adults with type-II diabetes with new 2 mg dose